Kardigan

Clinical-stage cardiovascular therapeutics company founded by MyoKardia veterans, developing personalized medicines for heart diseases with no approved treatments. Launched in 2025 with $300M in Series A, assembling a late-stage pipeline targeting dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis.